Evaluation of the safety and efficacy of micafungin in Japanese patients with deep mycosis: a post-marketing survey report

Abstract The safety and efficacy of micafungin were evaluated in a Japanese post-marketing survey involving 1,142 patients with deep mycosis caused by Candida or Aspergillus . The overall clinical response was 83.0%, and the respective responses for patients with candidiasis or aspergillosis were 86...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2011-10, Vol.17 (5), p.622-632
Hauptverfasser:	Hanadate, Tomoko, Wakasugi, Masahiro, Sogabe, Keizo, Kobayashi, Toshimitsu, Horita, Hisanori, Kawamura, Ikuo, Matsui, Keita, Sou, Masahiro, Hori, Yasuhiro, Hoshino, Yo
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Aspergillosis - drug therapy Aspergillus Aspergillus - isolation & purification Candida Candida - isolation & purification Candidiasis - drug therapy Echinocandins - adverse effects Echinocandins - therapeutic use Female Fungal infection Hematology, Oncology and Palliative Medicine Humans Infectious Diseases Japan Lipopeptides - adverse effects Lipopeptides - therapeutic use Male Medical Microbiology Medicine Medicine & Public Health Micafungin Middle Aged Original Article Post-marketing survey Product Surveillance, Postmarketing Prospective Studies Risk Factors Treatment Outcome Virology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!